Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore
Nuklearmedizin - NuclearMedicine | March 12, 2025 | Volume: 64 | Issue: 01 | Pages: 45-46
10.1055/s-0045-1804283